FDA
-
-
-
-
-
-
-
Gilead and Merck HIV pill shows strong results in Phase 3 trials
-
-
-
-
-
-
-
Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
-
-
-
-
-
-
-
Merck reaches deal to expand HIV drug access via ADAP programs
-
-
-
-
-
-
-
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resect
-
-
-
-
-
-
-
Merck and Gilead discontinue lung cancer drug combination trial
-
-
-
-
-
-
-
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
-
-
-
-
-
-
-
FDA approves Merck's IDVYNSO for HIV-1 treatment switch
-
330,173 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

